Annual vaccinations reduced the number of hospitalisations in children by 50%, not only...
FDA and NCATS launch CURE ID app for healthcare professionals
The US Food and Drug Administration (FDA) and the National Institutes of Health’s (NIH) National Center for Advancing Translational Sciences (NCATS) have launched a new app called CURE ID for health care professionals.
Valneva chikungunya vaccine shows promise in Phase I trial
French biotech company Valneva has announced positive data from the Phase I clinical trial of its chikungunya vaccine candidate, VLA1553.
VBI Vaccines and Brii Biosciences launch trial to treat HBV infection
VBI Vaccines and Brii Biosciences have initiated a Phase Ib/IIa clinical trial to test BRII-179 (VBI-2601) for the treatment of patients with chronic hepatitis B virus (HBV) infection.
Bavarian Nordic reports Phase III data for smallpox vaccine
Bavarian Nordic has reported data from the Phase III efficacy study of MVA-BN (Jynneos) vaccine, which is designed to prevent smallpox and monkeypox disease in adults aged above 18 years.
Gilead’s Biktarvy shows high virologic suppression in HIV patients
Gilead Sciences has reported positive three-year data from two Phase III clinical trials of Biktarvy in adults with human immunodeficiency virus-1 (HIV-1) infection.
Takeda’s dengue vaccine shows promise in Phase III trial
Takeda Pharmaceutical has reported positive results from the ongoing Phase III TIDES clinical trial of its dengue vaccine candidate, TAK-003.
Mologen begins lefitolimod’s Phase IIa trial to treat HIV
Germany’s Mologen has started a Phase IIa clinical trial to assess the combination of lefitolimod with new virus-neutralising antibodies to treat human immunodeficiency virus (HIV) patients.
Themis Bioscience and CEPI trial Lassa fever vaccine
Themis Bioscience and the Coalition for Epidemic Preparedness Innovations (CEPI) have commenced a Phase I clinical trial of Lassa fever vaccine candidate, MV-LASV.
GSK initiates Phase III programme of gepotidacin antibiotic
GlaxoSmithKline (GSK) has initiated the Phase III EAGLE clinical programme of its investigational antibiotic, gepotidacin, for the treatment of uncomplicated urinary tract infection (uUTI, acute cystitis) and urogenital gonorrhoea (GC).
UAB researchers to trial Bexsero vaccine for gonorrhoea
A research team at the University of Alabama at Birmingham (UAB) in the US has secured a contract to carry out a Phase II clinical trial of Bexsero vaccine to prevent gonorrhoea infection.